TRANSACTIONS - CEC CAPITAL

Cancel

Date：2024-10
/index.php?a=shows&catid=34&id=854
Recently, Dingzhi Dental, a leading brand and expert in complex dental implants in China, announced the closing of its Series A financing, raising several hundred million RMB, with Eight Roads as the sole investor. CEC Capital served as the exclusive
Cancel

Date：2024-10
/index.php?a=shows&catid=34&id=848
Wuhan-based iRegene, which aims to become a global leader in universal chemically induced cell therapy, recently announced the closing of its Series B financing, raising several hundred million RMB. The round was co-led by Orinno Capital and CDBT Group, w
Cancel

Date：2024-08
/index.php?a=shows&catid=34&id=842
MicroCyto announced that it has raised over 300 million yuan in Series A financing. The round was led by Beijing Jingguorui Investment, with participation from Beijing Medical and Health Industry Investment Fund, Shenzhen Capital Group, and Hebei Producti
Cancel

Date：2024-07
/index.php?a=shows&catid=34&id=839
MoonBiotech announced that it has recently completed a RMB 300 million Series C+ financing, solely invested by SDIC JULI Investment Management Co., LTD. This financing round follows the Series C funding involving SDIC Venture Capital, marking another inst
Cancel

Date：2024-05
/index.php?a=shows&catid=34&id=775
Recently, Blue Sail Medical (002382.SZ) announced that its cardiovascular and cerebrovascular business unit, Blue Sail Biosensors, has raised a total of RMB 1 billion in funding. The Series A2 round introduced an additional RMB 100 million, following a RM
Cancel

Date：2024-05

Exclusive Financial Advisor to MagAssist
Cancel

Date：2024-05
/index.php?a=shows&catid=34&id=773
Recently, Vision Medicals announced a successful completion of D+ round funding worth hundreds of millions RMB, with Kequan Fund as lead-investor and Tianxin Fund as co-investor. Funds raised in this round will be primarily used to promote the research an
Cancel

Date：2024-02
/index.php?a=shows&catid=34&id=771
On February 21, 2024, Yantai Dongcheng Biochemicals (002675) announced that its wholly-owned subsidiary, Yitai Pharmaceutical, intends to purchase the 99mTc-GSA injection and GSA cold kit (hereinafter referred to as the "target product") held by Rongcheng
Cancel

Date：2023-11
/index.php?a=shows&catid=34&id=767
This innovative platform specializes in recombinant protein drugs for metabolic diseases. QL Biopharm announces the completion of a nearly 200 million B+ round of financing. IMEIK and China US Green Fund led this financing round, with significant contrib